Molecular landscape of 
TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients. Here, ERBB2 is linked to breast carcinoma.